🔎 Trials Near Me

Akèy › Kansè kol › Tennessee

Etid klinik pou Kansè kol nan Tennessee

21 etid pou Kansè kol ap chèche patisipan nan sit nan Tennessee.

Vil nan Tennessee

Tèks ofisyèl etid la (Anglè)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • Tennessee Oncology PLLC, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • SCRI Oncology Partners, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

DESTINY-PANTUMOUR04

  • Research Site, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 25, 2026 · NCT07124000

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  • University of Tennessee Medical Center ( Site 6012), Knoxville
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 25, 2026 · NCT07216703

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Sarah Cannon - Tennessee Oncology, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Sarah Cannon Nashville, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07182149

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT04895709

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Erlanger Health, Inc, Chattanooga
  • The West Clinic, Germantown
  • SCRI Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  • Chattanooga's Program in Women's Oncology, Chattanooga
  • The West Clinic, PLLC dba West Cancer Center, Germantown
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jul 30, 2026 · NCT04831580

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • US Oncology Research LLC, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist (BHMCC), Memphis
  • Vanderbilt-Ingram Cancer Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 136, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 21, 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

  • Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT05941507

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.